Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer

scientific article published on 07 May 2019

Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/0008-5472.CAN-18-2529
P932PMC publication ID6606386
P698PubMed publication ID31064850

P50authorPeter S NelsonQ100440151
Kishor M. WasanQ111195095
P2093author name stringEmma S Tomlinson Guns
Gang Wang
Hans H Adomat
Colm Morrissey
Shancheng Ren
Michael E Cox
Jake W Noble
Ankur Midha
Jacob A Gordon
Fatemeh Derakhshan
Yen-Yi Lin
Collin C Collins
P2860cites workTargeting the adaptive molecular landscape of castration-resistant prostate cancerQ27022821
Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systemsQ28354246
Regulation of hepatic lipogenesis by the transcription factor XBP1Q28507784
Increased survival with enzalutamide in prostate cancer after chemotherapyQ29617511
Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell FateQ30234505
Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survivalQ30611108
Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterolQ33769607
Molecular characterization of human prostate carcinoma cell linesQ34266176
LNCaP model of human prostatic carcinoma.Q34271140
DNA measurement and cell cycle analysis by flow cytometry.Q34327880
Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI.Q34386663
Scavenger receptor class BI and selective cholesteryl ester uptake: partners in the regulation of steroidogenesisQ34922440
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variantsQ35249697
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitorsQ35532230
Autophagy as a modulator and target in prostate cancerQ35557084
Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall studyQ35581315
Technical pitfalls potentially affecting diagnoses in immunohistochemistryQ37104351
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancerQ37302524
Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activityQ37330041
Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer developmentQ37690024
Emerging roles of lipid metabolism in cancer metastasisQ37747513
Lipid-dependent regulation of the unfolded protein responseQ38301758
Hypercholesterolemia Is Associated with a Shorter Time to Castration-Resistant Prostate Cancer in Patients Who Have Undergone Androgen Deprivation TherapyQ38414609
Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate CancerQ38625967
Effect of simvastatin on castration-resistant prostate cancer cellsQ38760155
The current evidence on statin use and prostate cancer prevention: are we there yet?Q38800777
Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenograftsQ38846889
Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cellsQ39453252
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.Q39899629
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancerQ39954334
Cholesterol uptake and regulation in high-grade and lethal prostate cancers.Q40167193
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.Q40173819
A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease.Q40220899
High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancerQ40442759
The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence.Q40649810
Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell lineQ40689267
Up-regulated expression of scavenger receptor class B type 1 (SR-B1) is associated with malignant behaviors and poor prognosis of breast cancerQ40806334
A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancerQ41460209
Endoplasmic reticulum stress impairs cholesterol efflux and synthesis in hepatic cellsQ41962104
Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate CancerQ42019892
Cholesterol and prostate cancerQ42079833
Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease ProgressionQ42691638
Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders.Q42919393
Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivoQ43221614
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft modelQ43252963
Androgen receptor expression in androgen-independent prostate cancer cell linesQ43576703
High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinasesQ44269059
Association of increased autophagic inclusions labeled for beta-galactosidase with fibroblastic agingQ44547136
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.Q47759846
Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.Q50068799
Diagnostic and prognostic value of scavenger receptor class B type 1 in clear cell renal cell carcinomaQ50208515
Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.Q50517480
Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.Q51075713
The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.Q51495422
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.Q55519124
Use of statins and the risk of death in patients with prostate cancerQ86645078
Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)Q90839667
P433issue13
P304page(s)3320-3331
P577publication date2019-05-07
P1433published inCancer ResearchQ326097
P1476titleUpregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer
P478volume79

Reverse relations

cites work (P2860)
Q92316366Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Q92147548Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease
Q90746453Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis

Search more.